research Bicalutamide and the new perspectives for female pattern hair loss treatment: What dermatologists should know
Bicalutamide, a drug with a good safety profile, is a promising new treatment for female pattern hair loss.
Search
for
Sort by
Research
600-630 / 1000+ results 
research 44096 Efficacy in Subgroups related to Disease Characteristics in Patients with Alopecia Areata from BRAVE-AA1 and BRAVE-AA2
Baricitinib significantly improves hair regrowth in severe alopecia areata.
research PC-SPES Studies Promising, But Manufacturer Shuts Down
Promising cancer treatments were found, but the manufacturer closed.
research Relapsing nail fibrokeratoma: A case report on a teenager
Dutasteride is more effective than finasteride for hair growth with similar side effects.
research GLP-1 RAs and Skin Health: Exploring Dermatologic Side Effects and Therapeutic Interventions
GLP-1 receptor agonists can cause skin and hair issues due to rapid weight loss, but these can be managed with proper care and treatments.
research Effect of MK-386, a novel inhibitor of type 1 5 alpha-reductase, alone and in combination with finasteride, on serum dihydrotestosterone concentrations in men
research Alopecia in association with severe seborrhoeic dermatitis following combination antiretroviral therapy for acute retroviral syndrome
A man with HIV developed skin and hair issues after starting HIV treatment, which improved with topical treatment.
research Suspected upadacitinib-associated drug hypersensitivity mimicking disease exacerbation in ulcerative colitis
Upadacitinib can cause hypersensitivity that worsens ulcerative colitis symptoms.
research Dutasteride
Dutasteride effectively treats enlarged prostate, reduces prostate cancer risk, and promotes hair regrowth with few side effects.
research Dutasteride vs finasteride: assessment of differences in acute urinary retention rates and surgical risk outcomes in an elderly population aged > or =65 years.
Dutasteride is more effective than finasteride in reducing urinary retention and surgery risks in people aged 65 and older.
research A prospective, interventional, randomized, open-label, comparative, three-arm, parallel allocation, single-center clinical study to evaluate the effectiveness of Venusia CeraPlus cream and lotion as an adjuvant in the treatment of atopic dermatitis
Venusia CeraPlus cream and lotion effectively reduce eczema severity and improve skin moisture.
research 17α-Acetoxy-6-bromo-16β-methylpregna-4,6-diene-3,20-dione
A new compound with strong antiandrogenic effects was found, potentially useful for treating conditions like acne and prostate cancer.
research Dose-Dependent Increases in Carotid Intima-Media Thickness Associated with Oral Minoxidil but Not Dutasteride in Healthy Young Males: A Randomized Controlled Pharmacological Trial
Oral minoxidil can harm arteries at higher doses, while dutasteride may be safer.
research Uso do espironolactona no tratamento da acne vulgar na mulher adulta: uma revisão integrativa
Spironolactone is an effective and safe treatment for acne in adult women.
research EFFECT OF A COMBINATION OF DUTASTERIDE AND PARENTERAL TESTOSTERONE UNDECANOATE ON TESTOSTERONE DEFICIENCY SYMPTOMS AND PROSTATE IN PATIENTS WITH TESTOSTERONE DEFICIENCY AND BENIGN PROSTATIC HYPERPLASIA
The combination treatment reduced prostate size and improved testosterone deficiency symptoms but was less effective for sexual function.
research No increased risk of mood disorders in male androgenetic alopecia patients treated with dutasteride and finasteride: a retrospective cohort database study
Dutasteride and finasteride do not increase mood disorder risk in men with hair loss.
research Anti‐androgens may protect against severe COVID‐19 outcomes: results from a prospective cohort study of 77 hospitalized men
Anti-androgens, like finasteride, dutasteride, and spironolactone, may lessen the severity of COVID-19 in men, leading to fewer ICU admissions.
research ANTIANDROGENS AND THE SKIN
Antiandrogens can treat acne, hirsutism, and seborrhea by reducing sebum production and androgen action.
research Rational Design and Synthesis of 4-((1R,2R)-2-Hydroxycyclohexyl)-2(trifluoromethyl)benzonitrile (PF-998425), a Novel, Nonsteroidal Androgen Receptor Antagonist Devoid of Phototoxicity for Dermatological Indications
PF-998425 is a new, effective, and non-phototoxic treatment for skin conditions related to androgens.
research Efficacy of Skin Patting and Iontophoresis with Dutasteride Gel in Male and Menopausal Female Androgenetic Alopecia: A Pilot Study
Skin patting and iontophoresis with dutasteride gel improved hair growth in people with androgenetic alopecia.
research Use of 5-Alpha Reductase Inhibitors in Dermatology: A Narrative Review
5-Alpha Reductase Inhibitors are effective for male hair loss and some skin conditions, but their effectiveness in women and safety concerns require careful use.
research Simultaneous improvement of alopecia universalis and atopic dermatitis in a patient treated with a JAK inhibitor
A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.
research Using 5 alpha reductase inhibitors safely: What primary care physicians need to know
5 alpha reductase inhibitors can cause sexual, cognitive, and muscle side effects, and may slightly increase aggressive cancer risk.
research Acanthosis Nigricans during an HAIR-AN syndrome: "The Tree That Hides the Forest"
The case shows skin changes can indicate deeper health issues like insulin resistance, which are challenging to manage.
research Reply to: Oral dutasteride is a first‐line treatment for frontal fibrosing alopecia – There is insufficient evidence to recommend dutasteride as first‐line treatment in frontal fibrosing alopecia
research Novel DualSoftDrug Strategy Enables Developmentof Topical Androgen Receptor Antagonists with Enhanced Efficacy andOptimized Safety for Androgenetic Alopecia
A new topical treatment for hair loss is effective and safe with faster results.
research Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)
Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.
research Repurposing With Purpose: Treatment of Bachmann–Bupp Syndrome With Eflornithine and Implications for Other Polyaminopathies
Eflornithine improved symptoms in Bachmann–Bupp Syndrome patients.
research LB891 Analysis of breast health outcomes in women on oral 5-alpha reductase inhibitors: A single-center retrospective cohort study
5-alpha reductase inhibitors don't increase breast cancer or benign breast disorder risk in women.
research Hair regrowth in a patient with alopecia universalis and psoriasis vulgaris during deucravacitinib therapy
Deucravacitinib helped a man regrow hair significantly.